J
John H. Holcombe
Researcher at Eli Lilly and Company
Publications - 31
Citations - 2625
John H. Holcombe is an academic researcher from Eli Lilly and Company. The author has contributed to research in topics: Insulin & Insulin lispro. The author has an hindex of 20, co-authored 31 publications receiving 2538 citations.
Papers
More filters
Journal ArticleDOI
Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years.
David C. Klonoff,John B. Buse,Loretta L. Nielsen,Xuesong Guan,Christopher L. Bowlus,John H. Holcombe,Matthew Wintle,David G. Maggs +7 more
TL;DR: Adjunctive exenatide treatment for > or = 3 years in T2DM patients resulted in sustained improvements in glycemic control, cardiovascular risk factors, and hepatic biomarkers, coupled with progressive weight reduction.
Journal ArticleDOI
Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
Ralph A. DeFronzo,Ted Okerson,Prabhakar Viswanathan,Xuesong Guan,John H. Holcombe,Leigh MacConell +5 more
TL;DR: Although this study was limited by a 2-week duration of exposure, data demonstrate that, exenatide had a greater effect than sitagliptin to lower postprandial glucose and a more potent effect to increase insulin secretion and reduce insulin secretion in T2D patients.
Journal ArticleDOI
Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials.
John B. Buse,David C. Klonoff,Loretta L. Nielsen,Xuesong Guan,Christopher L. Bowlus,John H. Holcombe,David G. Maggs,Matthew Wintle +7 more
TL;DR: In patients with T2DM, adjunctive exenatide treatment for 2 years was generally well tolerated and resulted in a sustained reduction of HbA(1c), progressive reduction in weight, and improvements in HOMA-B, blood pressure, and the hepatic injury biomarkers, AST and ALT.
Journal ArticleDOI
Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes
Julio Rosenstock,Leslie Klaff,Sherwyn Schwartz,Justin Northrup,John H. Holcombe,Kenneth Wilhelm,Michael E. Trautmann +6 more
TL;DR: Exenatide plus lifestyle modification decreased caloric intake and resulted in weight loss in nondiabetic obesity with improved glucose tolerance in subjects with IGT and IFG.
Journal ArticleDOI
Combined therapy with insulin lispro Mix 75/25 plus metformin or insulin glargine plus metformin: a 16-week, randomized, open-label, crossover study in patients with type 2 diabetes beginning insulin therapy.
TL;DR: In this study population, Mix 75/25 plus metformin was associated with lower HbA(1c) than insulin glargine plus met formin, smaller rise in ppBG after breakfast and dinner, and higher proportion of patients achieving Hb a( 1c) < or =7.0%, with a slight increase in overall (but not nocturnal) hypoglycemia.